

Ahammune Biosciences, Veeda conduct human studies for vitiligo drug

24 June 2022 | News

The preliminary research for AB1001 was conducted at Ahammune's R&D laboratory based out of Pune



Pune-based Ahammune Biosciences and Ahmedabad-based Veeda Clinical Research have partnered for the first in human studies with Ahammune's investigational new drug- AB1001, being developed as a topical therapy for Vitiligo.

The preliminary research for AB1001 was conducted at Ahammune's R&D laboratory based out of Pune which demonstrates that this drug candidate is both safe and efficacious for vitiligo treatment. Both the companies – Ahammune Biosciences & Veeda Clinical Research – anticipate that this new drug has a great potential for the treatment of vitiligo.

Speaking about the new treatment, Co-founder and Executive Director of Ahammune Biosciences Private Limited, Dr. Parul Ganju, said, "Vitiligo is a debilitating disease where autoimmune attack to melanocytes results in the formation of white patches. The chronic nature of the disease and the lack of treatment options is distressing for the patients. Understanding this lacuna, we have identified new intervention pathway for the disease and have developed therapeutic molecules targeting this pathway. Our preclinical studies establish that our molecules have the potential to stop disease progression and also support repigmentation."